Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer

Phase 2MRT-2359ApalutamidePositive

AI Analysis

Summary

Monte Rosa Therapeutics has dosed the first patient in MODeFIRe-1, a Phase 2 study evaluating MRT-2359 in combination with apalutamide for patients with AR mutation-positive metastatic castration-resistant prostate cancer.

Clinical Trial Data

Phase

Phase 2

Importance:5/10

Sentiment:

0.40

Phase 2oncologyprostate cancerclinical trial initiationcombination therapy

Related Companies

$TRAX

Read the original article

Published by GlobeNewswire Clinical Studies on August 24, 2026 11:00 AM

Read Original